AMED Translational Research Grant (TR program)

AMED Translational Research Grant (TR program) sits under the Japan Agency for Medical Research and Development, the national medical R&D agency established on April 1, 2015. AMED reported a FY2026 budget of JPY 116.9 billion and oversees drug discovery, medical devices, regenerative medicine, infectious disease research, data use, and the medical innovation ecosystem, so the TR track belongs to a broad translational portfolio rather than a narrow disease silo. The program funds the path from basic study to clinical readiness. Its current structure includes preF, Seeds F, Seeds B, and Seeds C tracks, together with support for investigator-initiated clinical trials and clinical studies that aim for international standards. Nine regional translational support centers and core clinical research hospitals anchor the delivery model and give applicants a network to move discoveries toward patients. The best fit is a Japanese organization that can assemble a consortium and carry a therapeutic or device concept through staged development. Teams that can use the center network, keep the clinical question tight, and show a practical route from discovery to patient use are closest to the center of the program.

No upcoming rounds verified. Cadence: Annual.